ストックスクリーナーアプリを入手
326.34
1.97%
5.06
Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース
Alnylam Pharmaceuticals (ALNY) presents Vutrisiran ATTR-CM data at ACC.26 - MSN
Alnylam Pharmaceuticals (ALNY) Achieved Free Cash Flow Breakeven in 2025 - Yahoo Finance
RBC Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $450 - Moomoo
Alnylam Cardiovascular Data Highlights Potential Upside In ATTR-CM And Hypertension - Yahoo Finance
Antisense Oligonucleotides Market 2026-2033 | US$ 5,286.96 - openPR.com
Trading Systems Reacting to (ALNY) Volatility - Stock Traders Daily
Mach Natural Resources, Mesoblast And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Sahm
Is the options market predicting a spike in Alnylam Pharmaceuticals stock? - msn.com
Alnylam (ALNY) CHRO McLaughlin sells shares worth $1.27 million By Investing.com - Investing.com India
Alnylam (ALNY) CHRO McLaughlin sells shares worth $1.27 million - Investing.com
Alnylam (NASDAQ: ALNY) HR chief auto-sells shares to cover RSU taxes - Stock Titan
Alnylam (NASDAQ: ALNY) HR chief details stock and option holdings - Stock Titan
Is the options market signaling a potential surge in Alnylam Pharmaceuticals shares? - Bitget
Is the Options Market Predicting a Spike in Alnylam Pharmaceuticals Stock? - Zacks Investment Research
Book value per share of Alnylam Pharmaceuticals, Inc – LSE:0HD2 - TradingView
How New Vutrisiran Outcomes and Zilebesiran Safety Data Will Impact Alnylam Pharmaceuticals (ALNY) Investors - simplywall.st
Alnylam (NASDAQ: ALNY) sets 2026 virtual meeting, board elections and pay vote - Stock Titan
[144] ALNYLAM PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Alnylam Pharmaceuticals, Inc. (ALNY) Options Chain - Yahoo! Finance Canada
Alnylam Pharmaceuticals, Inc. (ALNY) stock price, news, quote and history - Yahoo Finance UK
Porphyria Treatment Market to Reach US$ 358.64 Million by 2032 - openPR.com
Alnylam announces proposed offering of $500M convertible senior notes - MSN
Perpetual Ltd Invests $2 Million in Alnylam Pharmaceuticals, Inc. $ALNY - marketbeat.com
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Aberdeen Group plc Has $52.83 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
10 Best Future Stocks to Buy for the Next 5 Years - Insider Monkey
Alnylam Pharmaceuticals (ALNY) Presents Vutrisiran ATTR-CM Data at ACC.26 - Insider Monkey
Alnylam CEO Greenstreet sells $2.23 million in stock - Investing.com
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After New Cardiovascular Data And Partnerships At ACC.26 - simplywall.st
ALNY Stock Price, Quote & Chart | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
Alnylam Data Update Highlights RNAi Potential And Undervalued Share Price - Sahm
Barclays Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $527 - Moomoo
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up - 24/7 Wall St.
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Combines Strong Growth with a Technical Breakout Setup - ChartMill
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat
Why Alnylam Pharmaceuticals Inc. (ALNY) is One of the Best High Growth Healthcare Stocks to Buy Now - insidermonkey.com
Hemophilia B Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Pfizer, Spark Therapeutics, Sanofi, Alnylam Pharma, CSL Behring, uniQure, Novo Nordisk - Barchart
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Alnylam (ALNY) Highlights Breakthrough Vutrisiran Data at ACC An - GuruFocus
Alnylam's (ALNY) Zilebesiran Shows Promising Phase 2 Safety Data - GuruFocus
Alnylam presents cardiovascular data at ACC conference - Investing.com
Alnylam heart drug showed gains seen in patients 11 years younger - Stock Titan
Morgan Stanley Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Maintains Target Price $360 - Moomoo
Redburn Atlantic Initiates Coverage of Alnylam Pharmaceuticals (ALNY) with Buy Recommendation - MSN
5 High Growth Healthcare Stocks to Buy Now - Insider Monkey
AI-Enabled ATTR-CM Care Pathway Initiative Might Change The Case For Investing In Alnylam Pharmaceuticals (ALNY) - simplywall.st
How Alnylam Pharmaceuticals Inc. (ALNY) Affects Rotational Strategy Timing - Stock Traders Daily
Assenagon Asset Management S.A. Sells 54,791 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
The European Commission Approves Alnylam’s AMVUTTRA - MSN
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Progress and Strategy in Transforming ATTR Amyloidosis Care and Expanding TTR FranchiseSlideshow (NASDAQ:ALNY) 2026-03-26 - Seeking Alpha
3 Stocks Trading Below Estimated Intrinsic Value By Up To 46.8% - simplywall.st
Vanguard amends 13G/A; reports 0 shares in Alnylam (ALNY) - Stock Titan
H.C. Wainwright reiterates Alnylam stock rating at buy, $510 target - Investing.com
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Alnylam Pharma (ALNY) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
SG Americas Securities LLC Buys 59,071 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
0.97%
0.80%
大文字化:
|
ボリューム (24 時間):